BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Vivos Therapeutics Inc

VVOSNASDAQ
Trade with Public
Trade with Public
$0.1505
0.016412.23%
가까이에: Sep 28, 5:00 PM EST
$0.1451
0.0118.2%
프리마켓: 6:59 AM EST
PRO
변동 이유?:Vivos Therapeutics shares are trading higher after the company announced th...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Vivos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vivos Therapeutics (VVOS).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$4Upside to Avg. PT+2567.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Jun 4, 2026Ascendiant CapitalLucas WardPT RaiseBuy$3→$3
Apr 22, 2026Ascendiant CapitalLucas WardPT CutBuy$6→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See analyst ratings page for full details.
Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.5 to $5.5.
Benzinga Newsdesk

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved